{"id":935714,"date":"2026-02-10T16:09:26","date_gmt":"2026-02-10T21:09:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\/"},"modified":"2026-02-10T16:09:26","modified_gmt":"2026-02-10T21:09:26","slug":"vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\/","title":{"rendered":"Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SAN CARLOS, Calif., Feb.  10, 2026  (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter and full year 2025 and provide a business update after market close on February 24, 2026. Company management will host a conference call and webcast beginning at 4:30 p.m. ET \/ 1:30 p.m. PT.<\/p>\n<p>To participate in the conference call, please dial 800-445-7795 (domestic) or 785-424-1699 (international), conference ID PCVX4Q25. A live webcast of the conference call will be available in the Investors &amp; Media section of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zj1X0eUPUjqw88ewBwxdlt7h31ml-ed76jAS-6AGA7u2IleOCymt4S1c7FrEsqH7dVbxnNYyd74qXeM66tcbYQ==\" rel=\"nofollow\" target=\"_blank\">www.vaxcyte.com<\/a>. A replay of the webcast will be available for approximately 30 days following the conference call.<\/p>\n<p>\n        <strong>About Vaxcyte <\/strong><br \/>\n        <br \/>Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in a Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company\u2019s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company\u2019s PCV franchise.<\/p>\n<p>Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF\u00ae, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company\u2019s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte\u2019s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zj1X0eUPUjqw88ewBwxdliXq6_QGUeWaRknMzpndeatFcvbR5nogRWwB-2PnE1sxuCcFQq4Vl19rfbrbN8SoYFlaIZFWnjtiX-DFAHwS7N5GeLaOMvdLkw0Kdlszv50dQ_kb07UAFBD8nAG-iGKPrQZl9mcD3qKXVeneJMPBvatwEG5dFI8MO54_aTevrt30iWqzl6J8LPYyMD-Xl9GQPgvQoqAKyPn23cSFIW7pzaqY5C0nb4qPydiN8qDrIVHExyu8enjxNnkj5u-0u7wy910UrUK81sDkKbrpgqqgsQx95Gu5zyWoarX9W5GMbusPcx2iPE2YWxCawmKdkQq4r-Lpwim50nHqkv_DedvS9ii-hl9YXicZYhdr3K4MkLoQtTnD78ykcjNDWvXqUt7Bk4xM4Fvz3U5QJa0DKRT2D4wf5Fb9D3D3Dxp0SE3-yMZqHUNTCNCFYaP_dxNPjQyNHWnQeCEsaXXNW-fiK_6kiUV9FEModxLKF6bbQM-EC3dkPY76Dhm3vDrLCT0Hng8T3gf0jf4ROE0hiHm2SsmSod_61TwjFfc_eMDPyuGMywk_4aDjEJcZF7inDeCyZcX92g7wvhg6DUALRS5kIrXY53fvJYkZMW-emMEHGGY_sSXJrijviBSZU4RSLiSGXw60fpx6__CmsnjznjBtfzuQAXw94Z8VZJhD5OLaFZRs3jUeWekTl8tvpP5R478yL840nsZHJ9CHoButAprv-YzjRZ_4q-WbbgOHukIIYlhIZRPTCwQrv3MazU9mMV1w9ncjDdbEyg5JmhnHdDxs_Cjv6hu4saQO5FON8MRgaoNE4hsEWglL4qHCFpc8wTbGeQnE1a9P3nK-zREtFP9I08kUHVWspk_eALhZ7Pd7I0saCRZjjpay3rNvm30NzT1zC5ZiN0sOLm_odfPpxj4RyfHOHdLAjRXykGgYEKUQnODYseQwDwiz6V3wFdRJ9XHgxMlPaf_e36_HYNFOfxSphl4nrOtFCq3dG_Z5FBwQ1HghXABOampe4hsgyDK_Oib3SZPfcGiZ9NdSkI__wwUbllYPe4TWF0iIO7PE2mSrAkdbN4iD\" rel=\"nofollow\" target=\"_blank\">www.vaxcyte.com<\/a>.<\/p>\n<p>\n        <strong><br \/>\n          <u>Contacts:<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p>Patrick Ryan, Executive Director, Corporate Affairs<br \/>Vaxcyte, Inc.<br \/>415-606-5135<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JSoJldg2uTxqVfO3-zTmlGR4aTPy5IvUnHggrJMxb798sAEESjmjIkEgnwHuO_JApls1_e4Qs8LTj-iNLJi8Ap34XBdCTU2zqxLi8vg-5bo=\" rel=\"nofollow\" target=\"_blank\">media@vaxcyte.com<\/a>\u00a0<\/p>\n<p>Jeff Macdonald, Executive Director, Investor Relations<br \/>Vaxcyte, Inc.<br \/>917-371-0940<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5HyoAtZ_gSJmqy-y5cRdDZ8eBkHvgdp-0_arskz9zB0BYZkCkI8BVFTQ2qh0xlh9u-Ciy5DDrdOhtd8qh7x2WGXV1zSQa5ub9TAhYBbwbuM=\" rel=\"nofollow\" target=\"_blank\">investors@vaxcyte.com<\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjI2NyM3NDE5MjE1IzIxOTU4MjQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDBiMzcwYzctMTIwZi00MDZiLTk0ZGYtMTFiMGI5ZTBlYTQ1LTEyMDczNzctMjAyNi0wMi0xMC1lbg==\/tiny\/Vaxcyte-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter and full year 2025 and provide a business update after market close on February 24, 2026. Company management will host a conference call and webcast beginning at 4:30 p.m. ET \/ 1:30 p.m. PT. To participate in the conference call, please dial 800-445-7795 (domestic) or 785-424-1699 (international), conference ID PCVX4Q25. A live webcast of the conference call will be available in the Investors &amp; Media section of the Company\u2019s website at www.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference call. About Vaxcyte &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-935714","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter and full year 2025 and provide a business update after market close on February 24, 2026. Company management will host a conference call and webcast beginning at 4:30 p.m. ET \/ 1:30 p.m. PT. To participate in the conference call, please dial 800-445-7795 (domestic) or 785-424-1699 (international), conference ID PCVX4Q25. A live webcast of the conference call will be available in the Investors &amp; Media section of the Company\u2019s website at www.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference call. About Vaxcyte &hellip; Continue reading &quot;Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-10T21:09:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjI2NyM3NDE5MjE1IzIxOTU4MjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026\",\"datePublished\":\"2026-02-10T21:09:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\\\/\"},\"wordCount\":394,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MjI2NyM3NDE5MjE1IzIxOTU4MjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\\\/\",\"name\":\"Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MjI2NyM3NDE5MjE1IzIxOTU4MjQ=\",\"datePublished\":\"2026-02-10T21:09:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MjI2NyM3NDE5MjE1IzIxOTU4MjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MjI2NyM3NDE5MjE1IzIxOTU4MjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\/","og_locale":"en_US","og_type":"article","og_title":"Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 - Market Newsdesk","og_description":"SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter and full year 2025 and provide a business update after market close on February 24, 2026. Company management will host a conference call and webcast beginning at 4:30 p.m. ET \/ 1:30 p.m. PT. To participate in the conference call, please dial 800-445-7795 (domestic) or 785-424-1699 (international), conference ID PCVX4Q25. A live webcast of the conference call will be available in the Investors &amp; Media section of the Company\u2019s website at www.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference call. About Vaxcyte &hellip; Continue reading \"Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-10T21:09:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjI2NyM3NDE5MjE1IzIxOTU4MjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026","datePublished":"2026-02-10T21:09:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\/"},"wordCount":394,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjI2NyM3NDE5MjE1IzIxOTU4MjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\/","name":"Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjI2NyM3NDE5MjE1IzIxOTU4MjQ=","datePublished":"2026-02-10T21:09:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjI2NyM3NDE5MjE1IzIxOTU4MjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjI2NyM3NDE5MjE1IzIxOTU4MjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935714","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=935714"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935714\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=935714"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=935714"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=935714"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}